The Bruker Avance™ IVDr NMR platform is now expanding with the launch of PhenoRisk PACS™ RuO, a research-use-only NMR test for molecular phenomics research on post COVID condition blood samples, using a multiplexed combination of biomarkers. It may indicate the personal risk related to cardiovascular disorders, type II diabetes, kidney disorders and the overall inflammatory status.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
YesIncluded in the Export Interest Directory?
NoCountries of Interest
1. All Countries listed below